Sanofi Replaces R&D Head, Maintains Neutral Rating

Overview

This report comments on Sanofi's recent announcement regarding R&D leadership change. Goldman Sachs points out that Dr. Paulo Fontoura will replace Dr. Houman Ashrafian as R&D Head, marking the first senior personnel change since the current CEO took office. Given the long development cycle in the pharmaceutical industry and the short tenure of the predecessor, the market holds a cautious view on whether he can quickly turn around the R&D situation. Goldman Sachs maintains its neutral rating and target price for Sanofi, believing its R&D rebuilding narrative still requires subsequent data verification.

Core views

Background and Impact of Personnel Change: Sanofi announced the replacement of the R&D head. The new appointee, Dr. Paulo Fontoura, comes from AI-native biotech company Xaira Therapeutics and previously led clinical development for neuroscience, immunology, etc. at Roche. The previous head, Dr. Houman Ashrafian, left after less than 3 years. Goldman Sachs believes that within the long R&D cycle of the pharmaceutical industry, this timeframe is insufficient to achieve meaningful organizational turnaround or have a substantial impact on ongoing late-stage trials. Therefore, while this change may bring a new atmosphere, it is unlikely to prove its impact on long-term success in the short term. Market Sentiment and Narrative: Although this may mark a new beginning for Sanofi's R&D organization after a series of disappointing pipelines, investors remain weak in confidence regarding the substitution capability of its development pipelines. Changes in R&D leadership, strategy, or focus may delay any potential recovery process. Therefore, Sanofi's R&D rebuilding story currently remains a process that 'needs to speak with results' (show-me), and the market will continue to focus on its follow-up performance. Valuation and Rating: Goldman Sachs maintains a neutral rating for Sanofi. Its valuation model uses a hybrid method combining DCF cash flow discounting and P/E multiples, each weighted at 50%. Based on a weighted average cost of capital (WACC) of 8% and a perpetual growth rate (TGR) of 0%, the DCF valuation is €87 per share; applying a target P/E of 9.5x based on 2027 expected EPS, the valuation is €92 per share. Mixing both yields a 12-month target price of €89 (ADR target price $51), consistent with before.

Analysis framework

Goldman Sachs adopts a combined approach of event-driven analysis and fundamental valuation. First, starting from industry characteristics, analyze the actual impact of R&D head tenure length on pipeline development of pharmaceutical companies, pointing out the logic that short-term tenure is difficult to change long-term R&D trajectories. Second, combine investor sentiment and market narrative to assess the potential psychological impact of this personnel change on stock prices. Finally, quantify the company's intrinsic value through a standard hybrid valuation model (DCF+PE) to ensure objectivity and continuity of the rating and target price.

Methodology notes

• Valuation MethodologySOTP Segment Valuation

  Hybrid Valuation Method (Weighted DCF and PE)

  The report uses a 50:50 weight hybrid valuation method combining DCF cash flow discounting and P/E multiple methods for valuation. This method combines absolute valuation (reflecting long-term cash flow creation ability) and relative valuation (reflecting market comparable company pricing levels), aiming to provide a more balanced value reference.

• Event Strategy and Behavioral FinanceExpectation Gap/Expectation Management

  Market Interpretation of R&D Leadership Change

  The report analyzes the market's expectations regarding the change in R&D heads. Due to the short previous tenure and the long industry R&D cycle, the market generally believes that results will not be seen in the short term, thus viewing this change as a 'wait-and-see' signal rather than an immediate positive catalyst, reflecting the market's wait-and-see attitude towards management execution.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sanofi (SASY.PA)

  Direct coverage target, directly affected by R&D leadership change event

  Strengths

  Possesses strong growth core products such as Dupixent, Altuviiio, Beyfortus; Valuation is attractive (expected FCF yield improvement)

  Weaknesses

  Pipeline replacement capability questioned; Previous R&D head tenure short, new head effectiveness needs time to verify

  Comparison

  Relative to other large European pharmaceutical companies in coverage universe (e.g., AstraZeneca, Novartis, etc.), Sanofi's R&D rebuilding progress is slower

  Risks

  Clinical pipeline data misses expectations; Core product sales growth slows; Exchange rate fluctuations affect EPS

Key data

• 12-Month Target Price (EUR)€89.00Unchanged, implies approx. 20% upside
• 12-Month Target Price (USD ADR)$51.00Unchanged, implies approx. 20.3% upside
• DCF Valuation AssumptionsWACC 8%, TGR 0%Implied per share valuation is €87
• PE Valuation Assumptions9.5x 2027E EPSImplied per share valuation is €92
• Current Stock Price (EUR)€74.14Closing price as of June 19, 2026

Impact & implications

This R&D leadership change is viewed as an initiative by Sanofi to revitalize its R&D pipelines, but Goldman Sachs believes its effects still need time to verify. For investors, this means Sanofi's stock price drivers in the short term will still rely on the sales performance of existing core products (such as Dupixent, Altuviiio, Beyfortus) and subsequent clinical data readouts, rather than immediate management dividends. Maintaining a neutral rating reflects the institution's judgment that the current valuation reasonably reflects fundamentals, neither overly pessimistic nor blindly optimistic.

Risks

• Clinical pipeline data readouts are disappointing, triggering concerns about Dupixent's long-term substitution strategy
• EPS consensus expectations are lowered due to foreign exchange factors and other operating income impacts
• Sales growth of Dupixent, Altuviiio, and Beyfortus falls below expectations

What to watch

• Key clinical pipeline data readout situations, including Phase II clinical trials
• Whether sales growth speeds of Dupixent, Altuviiio, and Beyfortus exceed expectations
• Capital allocation movements, such as whether to extend the current stock buyback plan or conduct M&A activities